20th Sep 2012 07:00
Cyprotex announces the launch of CellCiphr® Premier
20 September 2012 - Cyprotex PLC (AIM:CRX), the specialist preclinical contract research organisation (CRO), today announces the launch of CellCiphr® Premier, a High Content Screening (HCS) service that combines an extended panel of toxicologically-relevant endpoints with Cyprotex's unique system for classifying cellular responses to drug exposure, to provide one of the most reliable clinical hepatotoxicity predictors available on the market today.
HCS uses fluorescent dyes and fluorescently-labelled antibodies to stain specific regions of the cell which can be used to track processes that may indicate cellular toxicity. Setting up a HCS system is complex and requires a specific skill set, but for those pharmaceutical companies using this technology, it has become part of best practice to pick safer leads (DSEC 2011 Survey).
CellCiphr® Premier offers a panel of toxicologically-relevant endpoints in both replicating and metabolically competent cells which assess compounds at multiple time points to identify early and late stage toxicities. It also incorporates drug plasma concentrations to correct for drug exposure-related effects, which allows for more accurate prediction of potential drug toxicity. CellCiphr® Premier can help assess common toxicity signatures to identify candidates with the lowest potential risk for further drug development.
Commenting on this new offering, Dr. Anthony Baxter, the Chief Executive Officer of Cyprotex, said: "Drug-induced hepatotoxicity is major challenge in the Pharmaceutical Industry. With CellCiphr® Premier we have developed an offering which improves the prediction of hepatotoxicity over existing methods. This new offering complements our comprehensive portfolio of assays developed by Cyprotex to assess potential toxicity issues early in the drug development process, saving pharmaceuticals companies time and money".
Visit the Cyprotex website to find out more about our CellCiphr® Premier service.
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | www.cyprotex.com |
Singer Capital Markets Limited (broker to Cyprotex) | Tel: +44 (0) 20 3205 7500 |
Shaun Dobson Claes Spang
| www.singercm.com |
FTI Consulting | Tel: +44 (0) 20 7831 3113 |
Ben Brewerton Simon Conway Mo Noonan | www.fticonsulting.com
|
Notes to Editors
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, Boston in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.
Related Shares:
CRX.L